EWTX
Edgewise Therapeutics, Inc. · Healthcare
Insiders bought $199K of Edgewise Therapeutics, Inc. in the last 12 months
1 insider bought on 1 day.
EWTX over the last year
Largest buyers, last 12 months
EWTX after insider buys
3 months after each buy, from the first price a copier could get.
5 buys since 2021 with 3 months of prices.
Every filing
56 insider filings since 2021, newest first
Joanne M. Donovan · CMO
Alan J Russell · Chief Scientific Officer
John R Moore · General Counsel
Behrad Derakhshan · Chief Business Officer
Kevin Koch · President and CEO
Alan J Russell · Chief Scientific Officer
Joanne M. Donovan · CMO
Joanne M. Donovan · CMO
Joanne M. Donovan · CMO
Joanne M. Donovan · CMO
Badreddin Edris · Director
Jonathan C Fox · Director
Peter A. Thompson · Director and 10% owner
Orbimed Advisors LLC · Director and 10% owner
Joanne M. Donovan · CMO
Alan J Russell · Chief Scientific Officer
John R Moore · General Counsel
Behrad Derakhshan · Chief Business Officer
R Michael Carruthers · CFO
Joanne M. Donovan · CMO
John R Moore · General Counsel
R Michael Carruthers · CFO
Behrad Derakhshan · Chief Business Officer
Alan J Russell · Chief Scientific Officer
Kevin Koch · President and CEO
John R Moore · General Counsel
Behrad Derakhshan · Chief Business Officer
Peter A. Thompson · Director and 10% owner
Orbimed Advisors LLC · Director and 10% owner
R Michael Carruthers · CFO
Jonathan C Fox · Director
John R Moore · General Counsel
Alan J Russell · Chief Scientific Officer
Joanne M. Donovan · CMO
Kevin Koch · President and CEO
John R Moore · General Counsel
Peter A. Thompson · Director and 10% owner
Orbimed Advisors LLC · Director and 10% owner
Novo Holdings A/s · 10% owner
John R Moore · General Counsel
John R Moore · General Counsel
John R Moore · General Counsel
John R Moore · General Counsel
John R Moore · General Counsel
John R Moore · General Counsel
John R Moore · General Counsel
John R Moore · General Counsel
Alan J Russell · Chief Scientific Officer
Alan J Russell · Chief Scientific Officer
Alan J Russell · Chief Scientific Officer
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.